博路定联合肝动脉化疗对HBsAg(+)肝癌病人生存期的影响

Therapy using baraclude and hepatic artery chemoembolization(TACE)is helpful to prolong the survival for paitents with hepatocellular carcinoma(HCC)with coexisting active hepatitis B

目的观察博路定联合肝动脉化疗对HBsAg(+)肝癌病人肝功能和生存期的影响。方法36例HBsAg(+)无法手术的肝癌病人随机分为两组:对照组20例,治疗组16例。对照组:单纯行肝动脉化疗术。治疗组:先给予博路定两周后行肝动脉化疗术。观察乙肝病毒DNA清除率和生存时间。结果对照组和治疗组比较,3个月后HBV-DAN清除率分别为5%和100%(P<0·01),中位生存时间分别为5个月和8个月(P<0·01)。结论博路定能快速抑制病毒复制,提高HBsAg(+)肝癌病人患者生存时间。

Objective To observe the effect of therapy using baraclude and TACE on the liver biochemistry and survival for paitents with HCC with active hepatitis B. Methods 36 HCC paitents with coexisting active hepatitis B that cannot hepatectomy were randomized into two groups. Group Ⅰ （ n =20） received TACE only,Group Ⅱ （ n = 16） received baraclude and TACE. The suppression of HBVDNA and median survival in the two groups were observed and compared. Results In Group Ⅰ and Group Ⅱ ,the 3-month HBV-DNA suppression rate was 5% vs 100% （P〈0, 01）and median survival 5.0 vs 8.0 months（ P 〈 0. 01 ）. Conclusions Anti - viral therapy using baraclude may quickly suppress the HBV copy and prolong the survival for paitents with HCC with coexisting active hepatitis B.